Helsinn: 20 years in primary cancer supportive care.
Sergio Cantoreggi speaks to Henry Ireland, Commissioning Editor: Sergio Cantoreggi, PhD, is the Chief Scientific Officer and Global Head of Research and Development of the Helsinn Group, a mid-sized pharmaceutical company headquartered in Lugano, Switzerland, and focused on providing cancer supportive care solutions to oncology patients worldwide. Dr Cantoreggi has overall responsibility for all R&D activities of the Helsinn Group and has contributed to six major regulatory approvals of cancer supportive care agents in the USA, Europe and Japan. Dr Cantoreggi joined Helsinn Healthcare in 2000 as drug development scientist and was appointed Head of R&D in 2005. In 2010, he was promoted to his current role. From 1994 to 2000 he worked as toxicologist and regulatory scientist for Du Pont, Sandoz and Novartis. Prior to joining industry, Dr Cantoreggi completed a postdoctoral fellowship and earned a Master of Science degree in chemistry and a Doctoral degree in natural sciences with a thesis on the mechanism of chemical carcinogenesis from the Swiss Federal Institute of Technology in Zürich, Switzerland. Sergio Cantoreggi discusses Helsinn's role in cancer supportive care, describing current treatment options for patients, the company's pipeline and Helsinn's work in supporting the field as a whole.
Helsinn Healthcare SA, Via Pian Scairolo 9, 6912 Pazzallo, Switzerland.
Sergio
S
Cantoreggi
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D007494:Ireland; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D012106:Research
D000970:Antineoplastic Agents
cancer anorexia-cachexia; cancer supportive care; chemotherapy-induced diarrhea; chemotherapy-induced nausea and vomiting